Significant biosimilar activities this week include:
On 16 March 2020, Teva and Celltrion launched Herzuma (trastuzumab) in the US. Herzuma is indicated for the treatment of breast cancer, metastatic breast cancer and metastatic gastric cancer.
On 19 March 2020, the Centre for Biosimilars reported on a pair of biosimilar bills which were introduced to the US Congress in the 2 weeks prior. These bills include a 'shared savings' model designed to encourage physicians to switch patients to biosimilars, and a program that would allow $0 co-pays for seniors prescribed biosimilars.